Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.
Job A J VerdonschotJoão Pedro FerreiraPierpaolo PellicoriHans-Peter Brunner-La RoccaAndrew L ClarkFranco CosmiJoe CuthbertNicolas GirerdBeatrice MariottoniJohannes PetutschniggPatrick RossignolJohn G F ClelandFaiez ZannadStephane R B Heymansnull nullPublished in: Cardiovascular diabetology (2021)
Amongst patients at risk for HF, those with diabetes have higher plasma concentrations of proteins involved in inflammation and proteolysis. Diabetes does not influence the effects of spironolactone on the proteomic profile, and spironolactone produced anti-fibrotic, anti-remodelling, blood pressure and natriuretic peptide lowering effects regardless of diabetes status. Trial registration NCT02556450.
Keyphrases
- type diabetes
- cardiovascular disease
- heart failure
- glycemic control
- blood pressure
- end stage renal disease
- study protocol
- phase iii
- clinical trial
- ejection fraction
- phase ii
- newly diagnosed
- chronic kidney disease
- oxidative stress
- randomized controlled trial
- peritoneal dialysis
- metabolic syndrome
- heart rate
- adipose tissue
- label free
- patient reported outcomes